Primary appendiceal adenocarcinomas are estimated to occur in 1 to 2 per 1 000 000 persons per year ([@bib18]; [@bib24]; [@bib21]); among them, mucinous tumours constitute the most common histological type ([@bib5]). The histological classification of appendiceal mucinous neoplasms is controversial because of the frequent discrepancies between the histological findings and clinical behaviour. Previously, appendiceal mucinous neoplasms were classified as either an adenoma or an adenocarcinoma based on histological evidence of invasive growth ([@bib2]). However, unlike ordinary-type adenocarcinomas, appendiceal mucinous tumours may show intraperitoneal spreading even in the absence of high-grade cytological atypia or apparent invasive features ([@bib19]).

[@bib17] reviewed 107 cases of appendiceal mucinous neoplasms, and classified them into low-grade appendiceal mucinous neoplasms (LAMNs) and mucinous adenocarcinoma (MAC) based on their architectural complexity and degree of cytological atypia. Low-grade appendiceal mucinous neoplasms lack histological evidence of invasion and exhibit a villous or flat proliferation of mucinous epithelium with low-grade atypia. Meanwhile, MAC is characterised by high-grade cytological atypia and complex epithelial proliferation and often exhibits lymphatic and hematogenous invasion ([@bib17]; [@bib6]). Their study showed that while LAMNs may spread outside the appendix, LAMNs were associated with a better prognosis than MACs, indicating the prognostic relevance of this classification ([@bib17]). Currently, this classification has been adopted by the World Health Organization classification ([@bib6]).

Appendiceal mucinous tumours may spread throughout the peritoneal cavity, causing the slow but relentless accumulation of mucin, a condition known as pseudomyxoma peritonei ([@bib4]). Over time, mucin accumulation in the peritoneal cavity gradually causes massive symptomatic distension and functional gastrointestinal obstruction. The overall 10-year survival rates of pseudomyxoma peritonei were reported to be 21--45% ([@bib17]; [@bib16]), but a recent study reported a rate of 63% for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy ([@bib7]).

The molecular basis for the development of appendiceal mucinous tumours remains largely unknown. *KRAS* mutation is present in the majority of LAMNs and MACs ([@bib23]; [@bib10]; [@bib28]) and is virtually the only recurrent genetic abnormality identified so far. Microsatellite instability and p53 overexpression are reported to be infrequent ([@bib3]; [@bib10]; [@bib28]). Recently, other groups and we have reported the frequent presence of *GNAS* mutations in intraductal papillary mucinous neoplasm (IPMT) of the pancreas and villous adenoma of the colorectum ([@bib8]; [@bib26]; [@bib27]). Since these two neoplasms share some histopathological features with LAMN, including prominent mucin production and a villous architecture, we suspected the presence of a common genetic abnormality among these tumours. In the present study, we examined the presence of *GNAS* mutation and its functional significance in LAMNs.

Materials and methods
=====================

Study group
-----------

This study was approved by the Ethics Committee of the National Cancer Center, Tokyo, Japan. A total of 35 appendiceal mucinous tumours were identified in our case files between 1974 and 2012. We also retrieved a total of 186 mucinous tumours of extra-appendiceal origin, including those from the colorectum, ovary, pancreas, lung and breast. Tissue samples were provided by the National Cancer Center Biobank, Japan.

Histological analysis
---------------------

All the tissue samples were obtained by surgical resection and were fixed in 10% formalin and embedded in paraffin. Appendiceal mucinous neoplasms were histologically re-evaluated and classified into LAMN and MAC based on the definitions proposed by [@bib17]. Tumour samples of the primary site were not available for four LAMNs, and specimens obtained from peritoneal or omental deposits were analysed in these cases.

Immunohistochemistry was performed for all the appendiceal mucinous tumours. Deparaffinised 4-*μ*m-thick sections from each paraffin block were exposed to 0.3% hydrogen peroxide for 15 min to block endogenous peroxidase activity. Antigen retrieval was performed by autoclaving in a 10-mℳ citrate buffer (pH 6.0) for 10 min. Anti-MUC2 (Ccp58; 1 : 200 dilution; Novocastra, Newcastle upon Tyne, England) and anti-MUC5AC (CLH2; 1 : 200 dilution; Novocastra) were used as the primary antibodies. For staining, we used an automated stainer (Dako, Glostrup, Denmark) according to the vendor\'s protocol. ChemMate EnVision (Dako) methods were used for detection. The immunohistochemistry for MUC2 and MUC5AC were scored as: 0, \<10% positive cells; +1, 11--50% positive cells; +2, \>50% positive cells.

Mutation analysis
-----------------

In all, 10-*μ*m sections of the tumour specimens were stained briefly with haematoxylin and used for DNA extraction. The tumour epithelium was dissected using sterilised toothpicks under a microscope. The dissected samples were incubated in 50 *μ*l of DNA extraction buffer (50 mℳ Tris--HCL, pH 8.0, 1 mℳ ethylenediaminetetraacetic acid, 0.5% (v/v) Tween 20, 200 *μ*g ml^−1^ proteinase K) at 50 °C overnight. Proteinase K was inactivated by heating at 100 °C for 10 min. The samples were subjected to a polymerase chain reaction (PCR) using pairs of primers encompassing exons 8 and 9 of *GNAS* and exon 2 of *KRAS*, which contain frequently mutated regions ([Table 1](#tbl1){ref-type="table"}). The PCR products were electrophoresed in a 2% (w/v) agarose gel and were recovered using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). Isolated PCR products were sequenced using an Applied Biosystems 3130 Genetic Analyzer (Applied Biosystems Inc., Foster, CA, USA). When *GNAS* mutations were detected, the corresponding non-neoplastic tissues were additionally analysed to confirm their somatic nature.

In tumours concurrently harbouring two nucleotide substitutions in *GNAS*, the PCR products were subcloned using the TOPO TA cloning kit (Invitrogen, San Diego, CA, USA) and each clone was sequenced as described above.

Cell culture
------------

The colorectal cancer cell line HT29, which has wild-type *GNAS* and *KRAS* and mutant *BRAF* alleles (<http://www.sanger.ac.uk/genetics/CGP/CellLines/>), was obtained from the National Cancer Institute tumour repository (Frederick, MD, USA) and was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. HA-tagged rat *GNAS*^*R201H*^ cDNA ([@bib1]) was subcloned into the EF1a-IRES-Zeo plasmid to generate an EF1a-GNAS^R201H^-IRES-Zeo plasmid that expresses *GNAS*^*R201H*^ and the Zeocin-resistant gene as a single transcript under the control of the EF1a promoter. The HT29 cells were transfected with an EF1a-GNAS^R201H^-IRES-Zeo or control EF1a-IRES-Zeo plasmid and cultured in the presence of 20 *μ*g ml^−1^ of Zeocin for 3 weeks to obtain stable transfectants. The Zeocin-resistant cells were expanded in bulk culture, to avoid any biases resulting from cloning and were then subjected to further analysis.

For the cell proliferation assay, 1 × 10^5^ cells were seeded into 12-cell culture plates in triplicate and counted after 1--3 days. To inhibit PKA activity, 20 nℳ of H-89 (Sigma, St Louis, MO, USA) was added to the culture medium.

Reverse transcription--PCR
--------------------------

RNA extraction, reverse transcription and conventional PCR were performed using standard protocols. For conventional reverse transcription--PCR (RT--PCR), the PCR products were electrophoresed in an agarose gel and visualised under UV light with ethidium bromide staining. Quantitative RT--PCR (qRT--PCR) reactions were performed in triplicate using FastStart Universal Probe Master (Roche Applied Science, Penzberg, Germany). The expression level of each gene was determined using *GUSB* as a standard, as previously described ([@bib20]). The primer sequences and probes used are listed in [Table 1](#tbl1){ref-type="table"}.

cAMP assay
----------

Two thousand cells were seeded into 96-well cell culture plates and cultured overnight. After incubation in serum-free media containing 500 *μ*ℳ IBMX and 100 *μ*ℳ Ro20-1724 for 15 min, cAMP levels were measured using the cAMP-Glo Max Assay (Promega, Madison, WI, USA). The assays were done in triplicate.

Animal experiments
------------------

The mice used in the present study were maintained in barrier facilities according to the protocols approved by the Committee for Ethics in Animal Experimentation at the National Cancer Center, Japan. Five-week-old nu/nu athymic BALB/c mice were inoculated subcutaneously with 3 × 10^6^ tumour cells. Three weeks later, the mice were sacrificed and the tumours were weighed and analysed histologically. Ten xenografts were analysed for each group.

Statistical analysis
--------------------

The Fisher exact test was used to analyse each two-by-two table. Comparisons of continuous variables were using the Welch *t*-test. A value of *P*\<0.05 was considered statistically significant.

Results
=======

Histological re-evaluation showed that the 35 mucinous appendiceal tumours consisted of 32 LAMNs and 3 MACs ([Figure 1A--D](#fig1){ref-type="fig"}; [Table 2](#tbl2){ref-type="table"}). Sixteen LAMNs had serosal exposure as determined by histology, and 15 of them had peritoneal deposits. All the MACs had serosal exposure and two cases had peritoneal deposits. Lymph node metastasis was observed in two MACs but in none of the LAMNs. Immunohistochemically, all the LAMNs and two of the three MACs diffusely expressed MUC2 ([Figure 1E](#fig1){ref-type="fig"}). The focal or diffuse expression of MUC5AC was observed in 24 LAMNs and in all the MACs ([Figure 1F](#fig1){ref-type="fig"}).

Mutational analyses identified activating *GNAS* mutations in 16 LAMNs (50%) but in none of the MACs ([Figure 2](#fig2){ref-type="fig"}; [Table 2](#tbl2){ref-type="table"}). Two LAMNs had two *GNAS* mutations concurrently, and subcloning analyses showed that these mutations were on different alleles in both cases. No *GNAS* mutations were identified in the non-neoplastic tissues, indicating the somatic nature of these mutations. *KRAS* mutations were observed in 30 LAMNs (94%) and in all the MACs that were examined.

Statistical analyses showed that the presence of *GNAS* mutations was correlated with the expression of MUC5AC (+ or 2+ *vs* −, *P*=0.037), but not with age (⩽60 year-old *vs* \>60 year-old, *P*=1.0), sex (male *vs* female, *P*=1.0), or the presence of peritoneal deposits (present *vs* absent, *P*=0.47) among LAMNs. Because of the highly prevalent *KRAS* mutations and consistent MUC2 expression, these two factors were excluded from the analysis.

Based on the frequent presence of *GNAS* and *KRAS* mutations in LAMN, we further analysed mucinous tumours of other organs to clarify whether they shared a common set of genetic alterations. The analysis showed that *GNAS* mutations were highly common in IPMT of the pancreas but were rare or absent in mucinous tumours of other organs ([Table 3](#tbl3){ref-type="table"}). Thus, the presence of activating *GNAS* mutations is relatively organ-specific. The prevalence of *KRAS* mutations, on the other hand, was highly variable: these mutations frequently occurred in mucinous borderline tumours of the ovary, followed by MAC of the lung and IPMT of the pancreas. On the other hand, none of the MACs of the breast had *KRAS* mutations.

To probe the functional significance of the *GNAS* mutation, we established a colorectal cancer cell line stably expressing GNAS^R201H^ ([Figure 3A](#fig3){ref-type="fig"}, hereafter referred to as HT29-GNAS^R201H^ cells). The expression of GNAS^R201H^ protein was confirmed using western blotting (data not shown). As expected, the introduction of GNAS^R201H^ led to an elevated level of cAMP but did not alter cell proliferation *in vitro* ([Figure 3B and C](#fig3){ref-type="fig"}). However, morphologically, the HT29-GNAS^R201H^ cells showed the prominent formation of cytoplasmic vacuoles ([Figure 3D](#fig3){ref-type="fig"}). Furthermore, a quantitative RT--PCR analysis showed remarkable increases in *MUC2* and *MUC5AC* expression ([Figure 3E](#fig3){ref-type="fig"}). The expressions of *MUC2* and *MUC5AC* were partly downregulated by the addition of the PKA inhibitor H89, supporting the role of the cAMP-PKA pathway in the regulation of mucin production.

Next, we transplanted the HT29-GNAS^R201H^ cells and the controls subcutaneously into nu/nu athymic BALB/c mice. No significant difference in tumour growth was seen as determined by the tumour weight at 3 weeks after implantation ([Figure 3F](#fig3){ref-type="fig"}). A histological analysis showed that the transplanted HT29-GNAS^R201H^ cells exhibited more pronounced luminal formation compared with the controls ([Figure 3G](#fig3){ref-type="fig"}). Overall, the introduction of GNAS^R201H^ did not alter cell growth but significantly promoted mucin production in HT29 cells.

Discussion
==========

The present study identified *GNAS* mutations in half of the LAMNs that were examined. All the mutations that were identified have been previously reported in other tumours and have been shown to be activating mutations ([@bib12]; [@bib14]; [@bib8]; [@bib26]; [@bib27]). Additionally, in agreement with previous studies, a large majority of LAMNs and MACs harboured activating *KRAS* mutations ([@bib23]; [@bib10]; [@bib28]). Remarkably, *GNAS* mutations often co-existed with *KRAS* mutations also in various gastrointestinal tumours ([@bib8]; [@bib26]; [@bib15]; [@bib27]). The concurrent occurrence of *GNAS* and *KRAS* mutations in LAMNs is an additional example of the co-existence of these two genetic alterations and implies a functional interaction of these two oncogenes during tumourigenesis.

Among the tumours of digestive organs, *GNAS* mutations frequently occur in IPMT of the pancreas, villous adenomas of the colorectum, and pyloric gland adenomas of the stomach and duodenum ([@bib8]; [@bib26]; [@bib15]; [@bib27]). On the other hand, *GNAS* mutations are rare or absent in ordinary-type adenocarcinomas of these organs ([@bib13]; [@bib15]; [@bib27]). These observations imply that *GNAS* mutations might be preferentially associated with tumours with a benign or indolent biological behaviour. In this context, it is intriguing that MACs, which represent high-grade appendiceal mucinous tumours, lacked *GNAS* mutations; however, since only three MACs were included in our case series, further analyses are needed to confirm whether *GNAS* mutations are exclusively present in LAMNs among mucinous appendiceal tumours.

Because prominent mucin production is a common feature of LAMN and IPMN, both of which have frequent *GNAS* and *KRAS* mutations ([@bib8]; [@bib26]), we additionally analysed mucinous tumours of diverse organs for these mutations. The results showed that *GNAS* mutations were present in a rather organ-specific manner, whereas the prevalence of *KRAS* mutations was highly variable among each type of tumours. The distinct mutational profiles of *GNAS* and *KRAS* mutations might be potentially helpful in determining the origins of metastatic mucinous tumours in clinical situations.

*GNAS* encodes the *α*-subunit of a stimulatory G-protein (G*α*s), which transduces signals from seven-transmembrane receptors to the cAMP-generating enzyme adenylyl cyclase. *GNAS* mutations cause the constitutive activation of adenylyl cyclase and an elevated cAMP level, regardless of the presence or absence of receptor agonists ([@bib12]; [@bib14]). We used a colorectal cancer cell line HT29 for a functional analysis of mutant *GNAS* because this cell line is reportedly capable of differentiating into mucin-secreting cells upon appropriate stimuli ([@bib25]). As expected, the introduction of mutant *GNAS* resulted in an elevated level of cAMP, but did not promote cell growth either *in vitro* or *in vivo*. While mutant *GNAS* likely promotes tumourigenesis, our observation might be consistent with the indolent biological behaviour of LAMN.

On the other hand, the expressions of *MUC2* and *MUC5AC* were markedly induced by mutant *GNAS* and were partly inhibited by the PKA inhibitor, H89, implying a regulatory role of the G*α*s-cAMP-PKA pathway in mucin gene expression. Indeed, previous studies have reported that cAMP-dependent signalling induces mucin production in various cell types, including colorectal cancers ([@bib11]; [@bib9]; [@bib22]). These findings suggest that mutant *GNAS* might play a direct role in prominent mucin production, which is a hallmark of LAMN. On the other hand, considering the fact that LAMNs consistently express mucins (particularly MUC2) regardless of the presence or absence of *GNAS* mutations, additional mechanisms might be responsible for the mucin production in LAMN.

Even though mutant *GNAS* upregulated mucin production in HT29 cells, the mouse xenografts did not form mucin pools, a histological determinant of mucinous tumours. We also performed intraperitoneal injections of HT29-GNAS^R201H^ cells, but this procedure did not reproduce the phenotypes of pseudomyxoma peritonei and instead resulted in the formation of solid tumours (data not shown). This outcome is probably a limitation related to the use of established cancer cell lines, which have a higher proliferative activity than LAMN. While challenging, the modulation of non-transformed appendiceal or colon epithelium might be required to establish a model of pseudomyxoma peritonei.

The present study revealed the frequent presence of activating *GNAS* mutations in LAMN. *GNAS* mutations are also common in IPMT of the pancreas, but are rare or absent among mucinous tumours of other organs. Our analysis also suggested a direct role of mutant *GNAS* in mucin production in LAMN. Since exaggerated mucin production is responsible for the major complications in pseudomyxoma peritonei, the cAMP pathway might be a potential therapeutic target for this disease.
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![**Histology of appendiceal mucinous tumours.** (**A**--**E**) Histological and immunohistochemical findings of LAMN (**A**--**C**, **E**, **F**) and MAC (**D**). LAMN exhibiting a villous growth pattern (**A**). The tumour cells had low-grade cytological atypia. Mucin pools were present in the subserosal layer and were partly lined by mucinous epithelium (arrowheads). The stroma showed hyalinizing fibrosis (**B**). Peritoneal deposits of LAMN (**C**). Low-grade tumour cells grew on the surface of the omentum without evidence of stromal invasion (arrowheads) (**C**). MAC. Abundant mucin production and a frankly invasive growth pattern were evident. The tumour cells showed cytologically high-grade atypia, with a high nuclear--cytoplasmic ratio and prominent nucleoli (inset) (**D**). LAMN exhibiting diffuse MUC2 expression (**E**) and focal MUC5AC expression (**F**).](bjc201347f1){#fig1}

![*GNAS* and *KRAS* mutations in LAMNs. Representative *GNAS* and *KRAS* mutations identified in LAMNs. Missense mutations are indicated by the arrowheads. All the samples were sequenced using reverse primers.](bjc201347f2){#fig2}

![**Introduction of GNAS^R201H^ into the colorectal cancer cell line HT29 promotes mucin expression and luminal formation.** (**A**) Establishment of HT29 cells stably expressing a mutant *GNAS*. RT--PCR analysis showed the expression of the *GNAS*^*R201H*^ transgene in HT29-GNAS^R201H^ cells. The Zeocin-resistant gene (*Zeo*^*r*^) was expressed in HT29-GNAS^R201H^ cells and the mock transfectant. *ACTB* served as a positive control. (**B**) Elevated cAMP level in HT29-GNAS^R201H^ cells. The bars indicate averages+s.d. \**P*\<0.05. (**C**) Cell proliferation assay *in vitro*. The graphs indicate the average cell numbers of triplicate experiments. HT29-GNAS^R201H^ cells did not show altered cell proliferation. (**D**) Cell morphology *in vitro*. HT29-GNAS^R201H^ cells showed prominent intracytoplasmic vacuoles compared with parental HT29 and the mock transfectant. (**E**) Increased mucin expression in HT29-GNAS^R201H^ cells. Cells were cultured in the presence or absence of a PKA inhibitor, H89, and the *MUC2* and *MUC5AC* expression levels were determined using qRT--PCR. Bars indicate averages+s.d. \**P*\<0.05 (compared with parental HT29); \#*P*\<0.05 (compared with H89--). (**F**) Tumourigenicity *in vivo*. A total of 3 × 10^6^ cells were implanted into nude mice subcutaneously, and the tumours were weighed 3 weeks later. No significant difference in tumour weight was observed between the groups. The horizontal bars indicate the averages. (**G**) Histology of tumour xenografts. Parental HT29 and mock-transfected cells mainly showed a solid growth pattern with a few small intracytoplasmic lumina, whereas HT29-GNAS^R201H^ cells exhibited prominent luminal formation.](bjc201347f3){#fig3}

###### Primer sequences

                     **Application**     **Forward primer**        **Reverse primer**         **Probe**
  ------------------ ------------------- ------------------------- ------------------------- -----------
  *GNAS* exon 8      Mutation analysis   ACTGTTTCGGTTGGCTTTGGTGA   AGGGACTGGGGTGAATGTCAAGA         
  *GNAS* exon 9      Mutation analysis   GACATTCACCCCAGTCCCTCTGG   GAACAGCCAAGCCCACAGCA            
  *KRAS* exon 2      Mutation analysis   AGGCCTGCTGAAAATGACTG      GGTCCTGCACCAGTAATATGCA          
  *GNAS* transgene   RT--PCR             GACTGCCATCATCTTCGTGGTG    GAGTGGTGTAGCGAGCGAACT           
  *Zeo*^*r*^         RT--PCR             CAAGTTGACCAGTGCCGTTC      GACACGACCTCCGACCAC              
  *ACTB*             RT--PCR             AGACCTGTACGCCAACACAG      CGGACTCGTCATACTCCTGC            
  *MUC2*             qRT--PCR            GACCTCCAGCACAGTTTTATCA    GGTGGTCCTCATTGATCCAG         \#34
  *MUC5AC*           qRT--PCR            AGCACCAGTGCCCAAGTCT       ACTCCTGGCAGTCCATGC           \#43
  *GUSB*             qRT--PCR            CGCCCTGCCTATCTGTATTC      TCCCCACAGGGAGTGTGTAG         \#57

Abbreviation: RT--PCR=reverse transcription--polymerase chain reaction.

###### Clinicopathological features and mutation statuses of appendiceal mucinous tumours

        **Age/sex**            **Histology**            **Serosal exposure**   **Peritoneal implant**   **LN**   **MUC2**[a](#t2-fn2){ref-type="fn"}   **MUC5AC**[a](#t2-fn2){ref-type="fn"}        ***GNAS***        ***KRAS***
  ---- ------------- --------------------------------- ---------------------- ------------------------ -------- ------------------------------------- --------------------------------------- ---------------------- ------------
  1        30/M                    LAMN                          −                       −                −                      2+                                      −                             ---             c.35G\>A
  2        59/F                    LAMN                          −                       −                −                      2+                                     2+                          c.602G\>A          c.35G\>A
  3        72/M                    LAMN                          −                       −                −                      2+                                      −                             ---             c.34G\>T
  4        63/F                    LAMN                          −                       −                −                      2+                                     2+                          c.601C\>T          c.35G\>T
  5        62/F                    LAMN                          −                       −                −                      2+                                      −                             ---               ---
  6        53/M                    LAMN                          −                       −                −                      2+                                     1+                          c.602G\>A          c.38G\>A
  7        71/F                    LAMN                          −                       −                −                      2+                                     1+                             ---             c.35G\>T
  8        77/F                    LAMN                          −                       −                −                      2+                                     2+                          c.602G\>A            ---
  9        82/M                    LAMN                          −                       −                −                      2+                                     2+                          c.602G\>A          c.35G\>A
  10       72/M                    LAMN                          −                       −                −                      2+                                     1+                          c.602G\>A          c.35G\>T
  11       55/F                    LAMN                          −                       −                −                      2+                                     1+                             ---             c.38G\>A
  12       55/M                    LAMN                          −                       −                −                      2+                                      −                             ---             c.35G\>A
  13       72/M                    LAMN                          −                       −                −                      2+                                      −                             ---             c.35G\>A
  14       40/M                    LAMN                          −                       −                −                      2+                                      −                             ---             c.35G\>A
  15       84/F                    LAMN                          −                       −                −                      2+                                     2+                          c.602G\>A          c.35G\>T
  16       70/M                    LAMN                          −                       −                −                      2+                                     1+                             ---             c.35G\>A
  17       66/F                    LAMN                          \+                      −                −                      2+                                     2+                             ---             c.35G\>C
  18       56/F                    LAMN                          \+                      \+               −                      2+                                      −                             ---             c.35G\>A
  19       52/F                    LAMN                          \+                      \+               −                      2+                                     2+                          c.601C\>T          c.35G\>T
  20       82/F                    LAMN                          \+                      \+               −                      2+                                     1+                             ---             c.38G\>A
  21       47/M                    LAMN                          \+                      \+               −                      2+                                     2+                             ---             c.35G\>A
  22       52/F                    LAMN                          \+                      \+               −                      2+                                      −                     c.601C\>T, c.602G\>A    c.35G\>A
  23       59/M                    LAMN                          \+                      \+               −                      2+                                     2+                          c.601C\>T          c.35G\>T
  24       69/F                    LAMN                          \+                      \+               −                      2+                                     2+                             ---             c.35G\>T
  25       51/F                    LAMN                          \+                      \+               −                      2+                                     1+                             ---             c.35G\>T
  26       49/F                    LAMN                          \+                      \+               −                      2+                                     1+                             ---             c.35G\>T
  27       69/F                    LAMN                          \+                      \+               −                      2+                                     2+                          c.602G\>A          c.35G\>T
  28       64/F                    LAMN                          \+                      \+               −                      2+                                     2+                     c.601C\>T, c.602G\>A    c.38G\>A
  29       56/M       LAMN[b](#t2-fn3){ref-type="fn"}           N/A                      \+               −                      2+                                     2+                          c.601C\>T          c.35G\>A
  30       57/F       LAMN[b](#t2-fn3){ref-type="fn"}           N/A                      \+               −                      2+                                     2+                          c.601C\>T          c.35G\>A
  31       67/F       LAMN[b](#t2-fn3){ref-type="fn"}           N/A                      \+               −                      2+                                     2+                          c.601C\>A          c.35G\>A
  32       68/M       LAMN[b](#t2-fn3){ref-type="fn"}           N/A                      \+               −                      2+                                     2+                          c.601C\>T          c.35G\>T
  33       58/F                     MAC                          \+                      −                −                      2+                                     1+                             ---             c.34G\>A
  34       57/M                     MAC                          \+                      −                \+                     2+                                     1+                             ---             c.35G\>A
  35       51/M                     MAC                          \+                      \+               \+                      −                                     1+                             ---             c.35G\>A

Abbreviations: LN=lymph node metastasis; M=male; F=female; LAMN=low-grade appendiceal mucinous neoplasm; MAC=mucinous adenocarcinoma; N/A=not assessed.

The immunohistochemistry for MUC2 and MUC5AC were scored as: 0, \<10% positive cells; +1, 11--50% positive cells; +2, \>50% positive cells.

Tumour specimens of primary appendiceal tumours were unavailable and thus peritoneal (cases 29--31) or omental (case 32) deposits were analysed.

###### *GNAS* and *KRAS* mutations in mucinous tumours of diverse organs

                                                                          ***GNAS***   ***KRAS***                                                                       
  ------------ ---------------------------------------------------- ---- ------------ ------------ ---------------------- ------------------ ---------- ---- ---------- --------
  Appendix           Low-grade appendiceal mucinous neoplasm         32    16 (50%)        1             c.601C\>A             p.R201S        30 (94%)   1    c.34G\>T   p.G12C
                                                                                           6             c.601C\>T             p.R201C                   13   c.35G\>A   p.G12D
                                                                                           7             c.602G\>A             p.R201H                   1    c.35G\>C   p.G12A
                                                                                           2        c.601C\>T, c.602G\>A   p.R201C, p.R201H              11   c.35G\>T   p.G12V
                                                                                                                                                         4    c.38G\>A   p.G13D
                             Mucinous adenocarcinoma                 3        0                                                               3 (100%)   1    c.34G\>A   p.G12S
                                                                                                                                                         2    c.35G\>A   p.G12D
  Colorectum                 Mucinous adenocarcinoma                 33     3 (9%)         1             c.601C\>T             p.R201C        9 (27%)    4    c.35G\>A   p.G12D
                                                                                           2             c.602G\>A             p.R201H                   4    c.35G\>T   p.G12V
                                                                                                                                                         1    c.38G\>A   p.G13D
  Ovary                        Mucinous cystadenoma                  23     2 (9%)         1             c.602G\>A             p.R201H        7 (30%)    2    c.35G\>A   p.G12D
                                                                                           1        c.601C\>T, c.602G\>A   p.R201C, p.R201H              5    c.35G\>T   p.G12V
                            Mucinous borderline tumour               24       0                                                               21 (88%)   1    c.34G\>C   p.G12R
                                                                                                                                                         11   c.35G\>A   p.G12D
                                                                                                                                                         8    c.35G\>T   p.G12V
                                                                                                                                                         1    c.37G\>T   p.G13C
                           Mucinous cystadenocarcinoma               15       0                                                               8 (53%)    1    c.34G\>C   p.G12R
                                                                                                                                                         2    c.35G\>A   p.G12D
                                                                                                                                                         5    c.35G\>T   p.G12V
  Pancreas           Intraductal papillary mucinous neoplasm         37    30 (81%)        1             c.601C\>A             p.R201S        25 (68%)   1    c.34G\>A   p.G12S
                                                                                           15            c.601C\>T             p.R201C                   3    c.34G\>C   p.G12R
                                                                                           12            c.602G\>A             p.R201H                   7    c.35G\>A   p.G12D
                                                                                           2        c.601C\>T, c.602G\>A   p.R201C, p.R201H              13   c.35G\>T   p.G12V
                                                                                                                                                         1    c.38G\>A   p.G13D
  Lung          Mucinous adenocarcinoma[a](#t3-fn2){ref-type="fn"}   18       0                                                               14 (78%)   2    c.34G\>T   p.G12C
                                                                                                                                                         7    c.35G\>A   p.G12D
                                                                                                                                                         5    c.35G\>T   p.G12V
  Breast                     Mucinous adenocarcinoma                 36       0                                                                  0                          

*N*, total number of examined lesions; *n*, lesions with each mutation.

Formerly mucinous-bronchioloalveolar carcinoma.
